RxSight, Inc. to Present at the Wells Fargo Healthcare Conference
Get Alerts RXST Hot Sheet
Join SI Premium – FREE
ALISO VIEJO, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced plans to participate in the upcoming Wells Fargo Healthcare Conference.
RxSight’s management is scheduled to participate in a fireside chat Thursday, September 8, 2022, at 8:35 a.m. Pacific Time / 11:35 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation at: https://investors.rxsight.com/.
About RxSight, Inc.
RxSight, Inc. is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.
Company Contact:
Shelley Thunen
RxSight, Inc.
949-521-7830
[email protected]
Investor Relations Contact:
[email protected]
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Purpose Investments Inc. Announces Final September 2026 Distribution Rate for Purpose High Interest Savings Fund, Purpose US Cash Fund, Purpose Cash Management Fund, and Purpose USD Cash Management Fu
- Crypto News: Remittix Raises Its Final-Stage Price to $0.46 as Experts Outline $3.50 Dogecoin Price Prediction
- Global Health Congress 2026 Convenes Health System Leaders, Clinicians, Technologists, Investors and Innovators at the Yale Club of New York City, October 9th-11th
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Wells FargoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share